YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population CHICAGO, July 0…
(RTTNews) - MAIA Biotechnology Inc. (MAIA), a clinical-stage biopharmaceutical company, on Wednesday, announced the expansion of the Phase 2 THIO-101 trial for Ateganosine in treating non-small cell lung cancer to a second clinical testing…
(RTTNews) - MAIA Biotechnology, Inc. (MAIA), a clinical-stage biopharmaceutical company, provided a patient enrolment update for its pivotal Phase 3 trial, THIO-104, evaluating its investigational telomere-targeting agent, Ateganosine, as…
(RTTNews) - MAIA Biotechnology, Inc. (MAIA), a clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration, or FDA, has cleared an amendment to MAIA's IND to commence U.S enrollment for the expansion of the…
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index increasing 0.6% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that i…
(RTTNews) - MAIA Biotechnology, Inc. (MAIA) has strengthened its clinical ambitions with a recent $33 million capital raise, ensuring full funding for its pivotal Phase 3 trial of Ateganosine (THIO), a novel telomere-targeting anticancer t…
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts across therapeutic areas like Psoriasis, Asthma, C…
(RTTNews) - MAIA Biotechnology has reported a notable milestone in its ongoing Phase 2 THIO-101 trial, with eight patients living beyond two years after receiving its investigational therapy sequence of Ateganosine followed by Cemiplimab.…
(RTTNews) - MAIA Biotechnology, Inc. (MAIA), a clinical-stage immuno-oncology company, announced the pricing of its public offering of 20 million shares at a price of $1.50 per share to raise $30 million. MAIA intends to use the net procee…
Financing included participation by healthcare-dedicated investors alongside existing shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage bi…
CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has…
(RTTNews) - MAIA Biotechnology, Inc. (MAIA), a clinical-stage immuno-oncology company, provided 2025 corporate highlights, including Ateganosine, MAIA's lead drug for non-small cell lung cancer, and outlined key targeted milestones and gro…
MAIA Biotechnology, Inc. High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for ateganosine in NSCLC adva…
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is th…
Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-sta…
CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has…
CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint i…
CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that t…
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE Am…
Company starts enrollment in Romania for Phase 2 THIO-101 Part C study of ateganosine as a treatment for advanced non-small cell lung cancer patients CHICAGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)…
First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage…
Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceuti…
* MAIA Biotechnology (NYSE:MAIA) announced [https://seekingalpha.com/pr/20263719-maia-biotechnology-announces-736600-private-placement] that it has entered into definitive agreements for the purchase and sale of an aggregate of 0.60M share…
CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has…
A cancer drug developer has rocked Wall Street by implementing what is perhaps the most audacious crypto treasury strategy we have seen from a traditional biotech firm. MAIA Biotechnology (NYSE American: MAIA) announced on October 7 that i…
MAIA’s Board of Directors authorizes holdings of up to 90% of the Company’s liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MA…
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is th…
* MAIA Biotechnology (NYSE:MAIA [https://seekingalpha.com/symbol/MAIA]) announced on Monday that it has entered into definitive agreements for the purchase and sale of an aggregate of 1.74 million shares of common stock at $1.30 per share,…
CHICAGO, IL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has…
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals a…
* MAIA Biotechnology (NYSE:MAIA [https://seekingalpha.com/symbol/MAIA]) on Wednesday said that the National Institutes of Health [NIH] has awarded a $2.3 million grant for the expansion of its THIO-101 Phase 2 clinical trial evaluating ate…
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE…
CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted pos…
Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-sta…
CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that a…